PA8777701A1 - USO DE TEMPERATURA BAJA Y/O Ph BAJO EN EL CULTIVO DE CELULAS - Google Patents

USO DE TEMPERATURA BAJA Y/O Ph BAJO EN EL CULTIVO DE CELULAS

Info

Publication number
PA8777701A1
PA8777701A1 PA20088777701A PA8777701A PA8777701A1 PA 8777701 A1 PA8777701 A1 PA 8777701A1 PA 20088777701 A PA20088777701 A PA 20088777701A PA 8777701 A PA8777701 A PA 8777701A PA 8777701 A1 PA8777701 A1 PA 8777701A1
Authority
PA
Panama
Prior art keywords
low
cell culture
culture
low temperature
cell cultures
Prior art date
Application number
PA20088777701A
Other languages
English (en)
Inventor
Jose Manuel Gomes
Gregory Walter Hiller
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39493848&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PA8777701(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PA8777701A1 publication Critical patent/PA8777701A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C12N2500/33—Amino acids other than alpha-amino carboxylic acids, e.g. beta-amino acids, taurine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCION PROVEE UN NUEVO METODO PARA REDUCIR EL MAL PLEGAMIENTO Y AGREGACION DE PROTEINAS EN CULTIVOS DE CELULAS, MEDIANTE EL DESARROLLO DE CULTIVOS DE CELULAS A UNA TEMPERATURA REDUCIDA Y/O A pH REDUCIDO. COMO RESULTADO, LA CALIDAD DE LA PROTEINA PRODUCIDA EN EL CULTIVO DE CELULAS MEJORA ENORMEMENTE. POR LO TANTO, LA PRESENTE INVENCION FACILITA LAS MEJORAS EN LA EFICACIA DE PROTEINAS TERAPEUTICAS PRODUCIDAS EN CULTIVO DE CELULAS.
PA20088777701A 2007-04-23 2008-04-22 USO DE TEMPERATURA BAJA Y/O Ph BAJO EN EL CULTIVO DE CELULAS PA8777701A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91338207P 2007-04-23 2007-04-23

Publications (1)

Publication Number Publication Date
PA8777701A1 true PA8777701A1 (es) 2008-11-19

Family

ID=39493848

Family Applications (2)

Application Number Title Priority Date Filing Date
PA20088777701A PA8777701A1 (es) 2007-04-23 2008-04-22 USO DE TEMPERATURA BAJA Y/O Ph BAJO EN EL CULTIVO DE CELULAS
PA20088778001A PA8778001A1 (es) 2007-04-23 2008-04-23 Metodos de produccion de proteinas mediante la utilizacion de compuestos anti-senescencia

Family Applications After (1)

Application Number Title Priority Date Filing Date
PA20088778001A PA8778001A1 (es) 2007-04-23 2008-04-23 Metodos de produccion de proteinas mediante la utilizacion de compuestos anti-senescencia

Country Status (26)

Country Link
US (2) US20080274507A1 (es)
EP (2) EP2139986B1 (es)
JP (3) JP5557736B2 (es)
KR (3) KR20140132016A (es)
CN (3) CN105039473A (es)
AR (2) AR066238A1 (es)
AU (2) AU2008242632B2 (es)
BR (2) BRPI0810511A2 (es)
CA (2) CA2684727C (es)
CL (2) CL2008001156A1 (es)
CO (2) CO6241165A2 (es)
DK (2) DK2139987T5 (es)
ES (2) ES2424217T3 (es)
HK (2) HK1142095A1 (es)
HU (1) HUE034776T2 (es)
IL (2) IL201719A (es)
MX (2) MX2009011362A (es)
PA (2) PA8777701A1 (es)
PE (2) PE20090731A1 (es)
PL (2) PL2139986T3 (es)
PT (2) PT2139986T (es)
RU (2) RU2478702C2 (es)
SI (2) SI2139986T1 (es)
TW (2) TW200902708A (es)
WO (2) WO2008131375A1 (es)
ZA (1) ZA200907426B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
TW201516149A (zh) 2006-09-13 2015-05-01 Abbvie Inc 細胞培養改良
AU2008223133A1 (en) 2007-03-02 2008-09-12 Wyeth Use of copper and glutamate in cell culture for production of polypeptides
US20090042253A1 (en) * 2007-08-09 2009-02-12 Wyeth Use of perfusion to enhance production of fed-batch cell culture in bioreactors
WO2010034015A2 (en) 2008-09-22 2010-03-25 The Regents Of The University Of Colorado, A Body Corporate Modulating the alternative complement pathway
CN104974251A (zh) 2008-10-20 2015-10-14 Abbvie公司 在抗体纯化过程中的病毒灭活
JP5808249B2 (ja) * 2008-10-20 2015-11-10 アッヴィ・インコーポレイテッド プロテインａアフィニティークロマトグラフィーを用いる抗体の単離および精製
BR112012013330A2 (pt) * 2009-12-02 2017-03-28 Acceleron Pharma Inc composições e métodos para aumentar meia vida do soro de proteínas de fusão fc
RU2577972C2 (ru) 2010-04-26 2016-03-20 Новартис Аг Способ получения рекомбинантного полипептида
EP2660328A4 (en) 2010-12-28 2016-07-13 Chugai Pharmaceutical Co Ltd ANIMAL CELL CULTURE METHOD
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
EP2718328A4 (en) 2011-06-08 2014-12-24 Acceleron Pharma Inc COMPOSITIONS AND METHODS FOR INCREASING THE HALF TIME OF SERUM
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
AU2013309506A1 (en) 2012-09-02 2015-03-12 Abbvie Inc. Methods to control protein heterogeneity
AU2013381687A1 (en) 2013-03-12 2015-09-24 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
RU2718986C2 (ru) 2013-03-15 2020-04-15 Дженентек, Инк. Композиции клеточных культур с антиоксидантами и способы получения полипептидов
JP6689189B2 (ja) * 2013-03-26 2020-04-28 コヒラス・バイオサイエンシズ・インコーポレイテッド タンパク質産生方法
TW201446961A (zh) 2013-05-06 2014-12-16 Abbvie Inc 用於細胞培養之組合物及其使用方法
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
USD759075S1 (en) * 2014-04-11 2016-06-14 Nutonian, Inc. Display screen with graphical user interface
USD759076S1 (en) * 2014-04-18 2016-06-14 Nutonian, Inc. Display screen with graphical user interface
TWI743024B (zh) 2014-06-06 2021-10-21 美商健臻公司 灌注培養方法及其用途
EP3207132B1 (en) * 2014-10-15 2019-07-31 Alexion Pharmaceuticals, Inc. Methods of shifting an isoelectric profile of a protein product and uses thereof
AR104050A1 (es) * 2015-03-26 2017-06-21 Chugai Pharmaceutical Co Ltd Proceso de producción con iones de cobre controlados
TWI797060B (zh) 2015-08-04 2023-04-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
KR101936049B1 (ko) * 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
WO2017065559A1 (ko) * 2015-10-15 2017-04-20 (주)알테오젠 Igg fc 도메인을 가지는 융합 단백질의 생산방법
CN107460221B (zh) * 2016-06-02 2021-01-15 正大天晴药业集团股份有限公司 一种降低抗pd-l1抗体中蛋白聚合物的细胞培养方法
CN109952370B (zh) 2016-10-19 2023-09-08 豪夫迈·罗氏有限公司 用于产生免疫缀合物的方法
CN110494554A (zh) * 2017-02-17 2019-11-22 隆扎有限公司 用于生产生物产物变体的方法
WO2019079165A1 (en) * 2017-10-16 2019-04-25 Regeneron Pharmaceuticals, Inc. RAMAN IN SITU SPECTROSCOPY SYSTEMS AND METHODS FOR CONTROLLING PROCESSING VARIABLES IN CELL CULTURES
SG11202104417UA (en) * 2018-11-02 2021-05-28 Wuxi Biologics Ireland Ltd Cell culture process by intensified perfusion with continuous harvest and without cell bleeding
EP3935396A1 (en) * 2019-03-04 2022-01-12 Amgen Inc. In vivo reversibility of high molecular weight species
EP4087614A1 (en) 2020-01-09 2022-11-16 Mersana Therapeutics, Inc. Site specific antibody-drug conjugates with peptide-containing linkers
JP2022184798A (ja) * 2021-06-01 2022-12-13 ファイザー・インク ｓＦＧＦＲ３ポリペプチドを生産するための細胞培養方法
WO2023063611A1 (ko) * 2021-10-12 2023-04-20 프레스티지바이오로직스 주식회사 항체 집단의 제조 방법

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
JPH0396383A (ja) 1989-09-08 1991-04-22 Riso Kagaku Corp 画像形成装置
EP0417563B1 (de) * 1989-09-12 2000-07-05 F. Hoffmann-La Roche Ag TNF-bindende Proteine
GB8927546D0 (en) 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5610033A (en) 1990-04-25 1997-03-11 Novo Nordisk A/S Method of producing proteins with FVIII activity and/or FVIII derivatives
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
EP0571390B1 (en) * 1990-11-23 2000-03-08 Peptech Limited The delay, prevention and/or reversal of cell senescence
EP1400536A1 (en) * 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
DK0656946T4 (da) 1992-08-21 2010-07-26 Univ Bruxelles Immunoglobuliner uden lette kæder
US5399677A (en) 1993-12-07 1995-03-21 Genetics Institute, Inc. Mutants of bone morphogenetic proteins
US5516964A (en) 1994-01-21 1996-05-14 Sun Company, Inc. (R&M) Hydrocarbon isomerization using solid superacid catalysts comprising platinum metal
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US5830761A (en) * 1995-06-07 1998-11-03 Genetics Institute, Inc. Medium and methods for culturing mammalian cho cells
CA2229043C (en) * 1995-08-18 2016-06-07 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Protein/(poly)peptide libraries
JP4306813B2 (ja) 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
US5710023A (en) 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
US6146847A (en) * 1996-11-01 2000-11-14 Genespan Corporation Stabilized transient gene expression
CA2616914C (en) * 1996-12-03 2012-05-29 Abgenix, Inc. Egfr-binding antibody
TR200504220T2 (tr) 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
US7294481B1 (en) 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
JP3090657B1 (ja) 1999-08-09 2000-09-25 伸子 蓮山 ゼオライト製造方法およびゼオライト製造装置
AUPR038200A0 (en) * 2000-09-26 2000-10-19 Beta Peptide Foundation Pty Ltd, The Compositions and methods for delaying, preventing, rejuvenating or reversing senescence
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030040095A1 (en) * 2001-03-16 2003-02-27 Achille Arini Method for the production of pharmaceutically active recombinant proteins
US20040058445A1 (en) 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
US6544076B2 (en) 2001-07-10 2003-04-08 Alan L. Pocrass Dual function RJ connector
ATE464390T1 (de) * 2001-11-19 2010-04-15 Novo Nordisk As Verfahren zur herstellung von insulinverbindungen
CA2417689C (en) 2002-03-05 2006-05-09 F. Hoffmann-La Roche Ag Improved methods for growing mammalian cells in vitro
ES2557741T3 (es) * 2002-03-27 2016-01-28 Immunex Corporation Procedimientos para incrementar la producción de polipéptidos
GB0208041D0 (en) 2002-04-08 2002-05-22 Lonza Biologics Plc Method of culturing animal cells
JP2005532057A (ja) 2002-07-09 2005-10-27 バクスター・インターナショナル・インコーポレイテッド 細胞を培養するための動物性タンパク質非含有培地
CA2492267C (en) 2002-07-15 2013-09-10 Immunex Corporation Methods and media for controlling sialylation of proteins produced by mammalian cells
US6924124B1 (en) 2002-08-23 2005-08-02 Immunex Corporation Feeding strategies for cell culture
TWI312368B (en) 2002-12-23 2009-07-21 Bristol Myers Squibb Compan Mammalian cell culture processes for protein production
US20040265964A1 (en) 2003-04-25 2004-12-30 Martin Allen Inducers of recombinant protein expression
CN1565631A (zh) * 2003-06-27 2005-01-19 上海中信国健药业有限公司 肿瘤坏死因子受体－免疫球蛋白的融合蛋白用于急性肺损伤药物的用途
ATE464918T1 (de) * 2004-07-07 2010-05-15 Coloplast As Herstellung von hydrophilen überzügen mit einer 1,3-dioxolan-verbindung
TWI374935B (en) * 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
US7300773B2 (en) 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
US7426440B2 (en) * 2004-09-24 2008-09-16 Nutritional Bioscience Ltd. Repair and protection factor scoring method for bioactive agents
US20070102622A1 (en) 2005-07-01 2007-05-10 Olsen Richard I Apparatus for multiple camera devices and method of operating same
DE102005034616B4 (de) * 2005-07-18 2008-07-03 Elringklinger Ag Brennstoffzelleneinheit und Brennstoffzellenstapel
AR058140A1 (es) * 2005-10-24 2008-01-23 Wyeth Corp Metodo de produccion proteica utilizando compuestos anti-senescencia
KR101495549B1 (ko) * 2006-07-13 2015-02-25 와이어쓰 엘엘씨 당단백질의 생산
AU2008223133A1 (en) 2007-03-02 2008-09-12 Wyeth Use of copper and glutamate in cell culture for production of polypeptides
US20090042253A1 (en) 2007-08-09 2009-02-12 Wyeth Use of perfusion to enhance production of fed-batch cell culture in bioreactors

Also Published As

Publication number Publication date
ZA200907426B (en) 2010-08-25
WO2008131374A1 (en) 2008-10-30
IL201719A0 (en) 2011-08-01
AU2008242632A1 (en) 2008-10-30
HK1216261A1 (zh) 2016-10-28
CN101679943A (zh) 2010-03-24
CO6241166A2 (es) 2011-01-20
JP2014113161A (ja) 2014-06-26
DK2139987T3 (da) 2013-09-02
IL201720A (en) 2016-03-31
MX2009011362A (es) 2009-11-05
ES2424217T3 (es) 2013-09-30
ES2424217T9 (es) 2014-01-27
IL201720A0 (en) 2011-08-01
CA2684727C (en) 2018-09-04
EP2139987A1 (en) 2010-01-06
CO6241165A2 (es) 2011-01-20
TW200902709A (en) 2009-01-16
EP2139986B1 (en) 2017-09-06
CN101668845B (zh) 2015-11-25
CA2685552A1 (en) 2008-10-30
PE20090731A1 (es) 2009-07-15
TW200902708A (en) 2009-01-16
KR20100016271A (ko) 2010-02-12
MX2009011363A (es) 2009-11-05
ES2646090T3 (es) 2017-12-12
CA2684727A1 (en) 2008-10-30
AU2008242632B2 (en) 2013-11-28
CL2008001156A1 (es) 2009-01-16
JP5881755B2 (ja) 2016-03-09
RU2009138226A (ru) 2011-05-27
RU2009139054A (ru) 2011-05-27
US9988662B2 (en) 2018-06-05
AR066238A1 (es) 2009-08-05
PE20090153A1 (es) 2009-04-23
EP2139986A1 (en) 2010-01-06
JP5557736B2 (ja) 2014-07-23
PL2139986T3 (pl) 2018-01-31
AU2008242633A1 (en) 2008-10-30
PT2139987E (pt) 2013-08-22
DK2139987T5 (da) 2014-01-27
CN101668845A (zh) 2010-03-10
US20080269132A1 (en) 2008-10-30
HUE034776T2 (en) 2018-02-28
KR101540124B1 (ko) 2015-07-28
SI2139986T1 (sl) 2017-11-30
AR066239A1 (es) 2009-08-05
PT2139986T (pt) 2017-11-14
PL2139987T3 (pl) 2013-11-29
BRPI0810482A2 (pt) 2014-10-07
HK1142095A1 (zh) 2010-11-26
CL2008001159A1 (es) 2008-11-03
KR20140132016A (ko) 2014-11-14
JP2010524503A (ja) 2010-07-22
IL201719A (en) 2015-09-24
CN105039473A (zh) 2015-11-11
DK2139986T3 (en) 2017-10-02
CA2685552C (en) 2016-02-23
EP2139987B1 (en) 2013-07-03
SI2139987T1 (sl) 2013-09-30
BRPI0810511A2 (pt) 2014-10-07
RU2478702C2 (ru) 2013-04-10
PA8778001A1 (es) 2008-11-19
KR20100017211A (ko) 2010-02-16
WO2008131375A1 (en) 2008-10-30
AU2008242633B2 (en) 2014-09-18
EP2139987B9 (en) 2013-11-13
JP2010524504A (ja) 2010-07-22
KR101560421B1 (ko) 2015-10-15
US20080274507A1 (en) 2008-11-06

Similar Documents

Publication Publication Date Title
PA8777701A1 (es) USO DE TEMPERATURA BAJA Y/O Ph BAJO EN EL CULTIVO DE CELULAS
CR20110477A (es) Inhibidores de enzimas de proteina cinasa activadas por mitogeno p38
UY30816A1 (es) Compuestos activos en proteina quinasa, composicionesconteniéndolos y plicaciones
CR20110230A (es) Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38
GT200600316A (es) Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
SMT201600398B (it) Inibitori di proteina chinasi (varianti), uso di questi nel trattamento di malattie oncologiche e composizione farmaceutica basata su questi
CL2009001032A1 (es) Combinaciones de compuestos activos para controlar plagas animales; uso de las combinaciones; y procedimientos para controlar plagas animales.
CR20120371A (es) Antagonistas de pcsk9
CL2012002733A1 (es) Compuestos derivados de ácido 1-amino-2-ciclopropiletilborónico, inhibidores de proteasoma; composición farmacéutica; uso en el tratamiento del cáncer; procedimiento de preparacion; compuestos intermediarios.
CL2011002756A1 (es) Anticuerpo que se enlaza a la proteina del complemento c3b humana o de cinomolgo; composicion farmaceutica, acido nucleico, vector y celula huesped que comprenden dicho anticuerpo; uso para tratar degeneracion macular relacionada con la edad.
CL2011001485A1 (es) Compuestos heterociclicos nitrogenados sustituidos; inhibidor de proteinas anti-apoptoticas bc1-2; sus composiciones farmaceuticas; y su uso para tratar enfermedades causadas por un exceso de plaquetas, cancer de pulmon de celulas pequeñas, trombocitemia esencial, policitemia vera, restenosis.
EA201171494A1 (ru) Миметики белка smac
AR061171A1 (es) Proteinas de union al factor de crecimiento de hepatocitos (fch)
CU23632A1 (es) Métodos para la identificación de candidatos terapéuticos contra enfermedades causadas por flavivirus y moléculas antivirales.
AR059964A1 (es) Metodos para reducir la aglomeracion de proteina
EA201391632A1 (ru) Аминокислотные последовательности, направленные против il-17a, il-17f и/или il-17a/f, и содержащие их полипептиды
CR20110470A (es) Proteínas de union a il-17
HN2008001104A (es) Compuestos para anticuerpos de dickpf-1 y70-4
BRPI0514340A (pt) formulações de estabilização
CL2011000086A1 (es) Anticuerpo aislado o proteina funcional contra el polipeptido baffr que inhibe la proliferacion de celulas b; secuencia nucleotidicas de dicho anticuerpo; vector y celula huesped que comprende dicha secuencia; y su uso para tratar enfermedades autoinmunes o neoplasias de celulas b.
GT200600264A (es) Modificaciones cristalinas de piraclostrobina
EA201170813A1 (ru) Способы и композиции на основе pcv2 для лечения свиней
EA201491850A1 (ru) Набор, содержащий кондиционирующую композицию для волос и активирующую композицию
AR113492A2 (es) Furina recombinante libre de proteínas sustancialmente animal y métodos para producirla
AR089752A1 (es) Anticuerpos anti-lrp5 y metodos de uso